FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108262602> ?p ?o ?g. }

• W2108262602 abstract "The Chinese government has provided health services to those infected by the human immunodeficiency virus (HIV) under the acquired immunodeficiency syndrome (AIDS) care policy since 2003. Detailed research on the actual expenditures and costs for providing care to patients with AIDS is needed for future financial planning of AIDS health care services and possible reform of HIV/AIDS-related policy. The purpose of the current study was to determine the actual expenditures and factors influencing costs for untreated AIDS patients in a rural area of China after initiating highly active antiretroviral therapy (HAART) under the national Free Care Program (China CARES). A retrospective cohort study was conducted in Yunnan and Shanxi Provinces, where HAART and all medical care are provided free to HIV-positive patients. Health expenditures and costs in the first treatment year were collected from medical records and prescriptions at local hospitals between January and June 2007. Multivariate linear regression was used to determine the factors associated with the actual expenditures in the first antiretroviral (ARV) treatment year. Five ARV regimens are commonly used in China CARES: zidovudine (AZT) + lamivudine (3TC) + nevirapine (NVP), stavudine (D4T) + 3TC + efavirenz (EFV), D4T + 3TC + NVP, didanosine (DDI) + 3TC + NVP and combivir + EFV. The mean annual expenditure per person for ARV medications was US$2,242 (US$1 = 7 Chinese Yuan (CNY)) among 276 participants. The total costs for treating all adverse drug events (ADEs) and opportunistic infections (OIs) were US$29,703 and US$23,031, respectively. The expenses for treatment of peripheral neuritis and cytomegalovirus (CMV) infections were the highest among those patients with ADEs and OIs, respectively. On the basis of multivariate linear regression, CD4 cell counts (100-199 cells/μL versus <100 cells/μL, P = 0.02; and ≥200 cells/μL versus <100 cells/μL, P < 0.004), residence in Mangshi County (P < 0.0001), ADEs (P = 0.04) and OIs (P = 0.02) were significantly associated with total expenditures in the first ARV treatment year. This is the first study to determine the actual costs of HIV treatment in rural areas of China. Costs for ARV drugs represented the major portion of HIV medical expenditures. Initiating HAART in patients with higher CD4 cell count levels is likely to reduce treatment expenses for ADEs and OIs in patients with AIDS." @default.
• W2108262602 created "2016-06-24" @default.
• W2108262602 creator A5010316531 @default.
• W2108262602 creator A5017261683 @default.
• W2108262602 creator A5028202597 @default.
• W2108262602 creator A5029442024 @default.
• W2108262602 creator A5041739922 @default.
• W2108262602 creator A5051876003 @default.
• W2108262602 creator A5064754725 @default.
• W2108262602 date "2011-01-17" @default.
• W2108262602 modified "2023-10-14" @default.
• W2108262602 title "Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs" @default.
• W2108262602 cites W1539935245 @default.
• W2108262602 cites W1573558157 @default.
• W2108262602 cites W1938727774 @default.
• W2108262602 cites W1969791248 @default.
• W2108262602 cites W1981655325 @default.
• W2108262602 cites W1987146942 @default.
• W2108262602 cites W2006341180 @default.
• W2108262602 cites W2012941855 @default.
• W2108262602 cites W2014859893 @default.
• W2108262602 cites W2019023077 @default.
• W2108262602 cites W2021484232 @default.
• W2108262602 cites W2035937873 @default.
• W2108262602 cites W2059614860 @default.
• W2108262602 cites W2065793718 @default.
• W2108262602 cites W2072728060 @default.
• W2108262602 cites W2075662875 @default.
• W2108262602 cites W2084000360 @default.
• W2108262602 cites W2098131455 @default.
• W2108262602 cites W2104810332 @default.
• W2108262602 cites W2108259145 @default.
• W2108262602 cites W2111255260 @default.
• W2108262602 cites W2118594952 @default.
• W2108262602 cites W2150662265 @default.
• W2108262602 cites W2169029345 @default.
• W2108262602 cites W2315806009 @default.
• W2108262602 cites W2318289184 @default.
• W2108262602 doi "https://doi.org/10.1186/1741-7015-9-6" @default.
• W2108262602 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3025874" @default.
• W2108262602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21241494" @default.
• W2108262602 hasPublicationYear "2011" @default.
• W2108262602 type Work @default.
• W2108262602 sameAs 2108262602 @default.
• W2108262602 citedByCount "16" @default.
• W2108262602 countsByYear W21082626022012 @default.
• W2108262602 countsByYear W21082626022013 @default.
• W2108262602 countsByYear W21082626022015 @default.
• W2108262602 countsByYear W21082626022016 @default.
• W2108262602 countsByYear W21082626022018 @default.
• W2108262602 countsByYear W21082626022020 @default.
• W2108262602 countsByYear W21082626022023 @default.
• W2108262602 crossrefType "journal-article" @default.
• W2108262602 hasAuthorship W2108262602A5010316531 @default.
• W2108262602 hasAuthorship W2108262602A5017261683 @default.
• W2108262602 hasAuthorship W2108262602A5028202597 @default.
• W2108262602 hasAuthorship W2108262602A5029442024 @default.
• W2108262602 hasAuthorship W2108262602A5041739922 @default.
• W2108262602 hasAuthorship W2108262602A5051876003 @default.
• W2108262602 hasAuthorship W2108262602A5064754725 @default.
• W2108262602 hasBestOaLocation W21082626021 @default.
• W2108262602 hasConcept C126322002 @default.
• W2108262602 hasConcept C142462285 @default.
• W2108262602 hasConcept C159110408 @default.
• W2108262602 hasConcept C160735492 @default.
• W2108262602 hasConcept C162324750 @default.
• W2108262602 hasConcept C167135981 @default.
• W2108262602 hasConcept C203014093 @default.
• W2108262602 hasConcept C2426938 @default.
• W2108262602 hasConcept C2522874641 @default.
• W2108262602 hasConcept C2777447569 @default.
• W2108262602 hasConcept C2777869810 @default.
• W2108262602 hasConcept C2779130552 @default.
• W2108262602 hasConcept C2779889181 @default.
• W2108262602 hasConcept C2780216070 @default.
• W2108262602 hasConcept C2780593183 @default.
• W2108262602 hasConcept C2780727368 @default.
• W2108262602 hasConcept C2781432083 @default.
• W2108262602 hasConcept C2993143319 @default.
• W2108262602 hasConcept C3013748606 @default.
• W2108262602 hasConcept C50522688 @default.
• W2108262602 hasConcept C512399662 @default.
• W2108262602 hasConcept C71924100 @default.
• W2108262602 hasConcept C99454951 @default.
• W2108262602 hasConceptScore W2108262602C126322002 @default.
• W2108262602 hasConceptScore W2108262602C142462285 @default.
• W2108262602 hasConceptScore W2108262602C159110408 @default.
• W2108262602 hasConceptScore W2108262602C160735492 @default.
• W2108262602 hasConceptScore W2108262602C162324750 @default.
• W2108262602 hasConceptScore W2108262602C167135981 @default.
• W2108262602 hasConceptScore W2108262602C203014093 @default.
• W2108262602 hasConceptScore W2108262602C2426938 @default.
• W2108262602 hasConceptScore W2108262602C2522874641 @default.
• W2108262602 hasConceptScore W2108262602C2777447569 @default.
• W2108262602 hasConceptScore W2108262602C2777869810 @default.
• W2108262602 hasConceptScore W2108262602C2779130552 @default.
• W2108262602 hasConceptScore W2108262602C2779889181 @default.
• W2108262602 hasConceptScore W2108262602C2780216070 @default.
• W2108262602 hasConceptScore W2108262602C2780593183 @default.
• W2108262602 hasConceptScore W2108262602C2780727368 @default.

• next